HPV L1 capsid protein expression in squamous intraepithelial lesions of cervix uteri and its relevance to disease outcome
- 207 Downloads
The purpose of this study was to investigate the usefulness of immunocytochemical detection of HPV L1 capsid protein expression in predicting the course of cervical intraepithelial neoplasia.
It is known that most of the low grade dysplastic lesions of cervix uteri regress spontaneously and only some will progress to high grade dysplastic lesions. HPV L1 capsid protein represents about 90% of the total protein on the surface of the virus and can be detected in mild to moderate dysplasia and rarely in severe dysplasia.
Pap smears from 65 women, in whom diagnoses of LSIL (n = 43) and HSIL (n = 22) were made on cytology and histology specimens, were immunocytochemically stained using antibody against HPV L1capsid protein. The results of immunocytochemical analysis were correlated with the outcome during the 24-month follow-up. p value <0.05 was considered significant.
The immunostaining reaction for L1 capsid protein was positive in 28 cases (65.1%) of LSIL while 15 (34.9%) cases of LSIL and all of the 22 cases of HSIL were negative (p < 0.001). After 24 months of follow-up, among the 28 L1-positive LSIL cases, we found a 60.7% (17/28) spontaneous regression rate, whereas in the 15 L1-negative LSIL patients, the regression rate was 33.3% (5/15). Out of the 22 HSIL cases, 13.6% (3/22) had regression.
Our data support that immunocytochemical detection of HPV-L1 protein could present prognostic information about the evolution of early dysplastic cervical lesions and can be useful in predicting their biologic potential.
KeywordsL1 capsid protein Cervical intraepithelial neoplasia Human papilloma virus Pap smear
Cervical intraepithelial neoplasia
Human papilloma virus
High-grade squamous intraepithelial lesion
Low-grade squamous intraepithelial lesion
Negative predictive value
Positive predictive value
Squamous cell carcinoma
Conflict of interest
The authors declare that they have no conflict of interests.
- 2.Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. N Engl J Med 348:518–527PubMedCrossRefGoogle Scholar
- 4.Addis IB, Hatch KD, Berek JS (2006) Intraepithelial disease of the cervix, vagina and vulva.In: Berek and Novak’s Gynecology, 14rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 561–599Google Scholar
- 5.Agorastos T, Miliaras D, Lambropoulos AF, Chrisafi S, Kotsis A, Manthos A, Bontis J (2005) Detection and typing of human papillomavirus DNA in uterine cervices with coexistent grade I and grade III intraepithelial neoplasia: biologic progression or independent lesions? Eur J Obstet Gynecol Reprod Biol 121:99–103PubMedCrossRefGoogle Scholar
- 9.Trimble CL, Piantadosi S, Gravitt P, Ronnett B, Pizer E, Elko A, Wilgus B, Yutzy W, Daniel R, Shah K, Peng S, Hung C, Roden R, Wu TC, Pardoll D (2005) Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 11:4717–4723PubMedCrossRefGoogle Scholar
- 11.Kitchener HC, Castle PE, Cox JT (2006) Achievements and limitations of cervical cytology screening. Vaccine 24(Suppl 3):S3/63–S3/70Google Scholar
- 20.Ungureanu C, Socolov D, Anton G, Mihailovici MS, Teleman S, Rom J (2010) Immunocytochemical expression of p16INK4a and HPV L1 capsid proteins as predictive markers of the cervical lesions progression risk. Morphol Embryol 51:497–503Google Scholar
- 22.Negri G, Bellisano G, Zannoni GF, Rivasi F, Kasal A, Vittadello F, Antoniazzi S, Faa G, Ambu R, Egarter-Vigl E (2008) p16 ink4a and HPV L1 immunohistochemistry is helpful for estimating the behavior of low-grade dysplastic lesions of the cervix uteri. Am J Surg Pathol 32:1715–1720PubMedCrossRefGoogle Scholar
- 26.Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J (2009) Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 101:88–99PubMedCrossRefGoogle Scholar